These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23506979)

  • 1. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
    Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
    Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
    Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
    Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.
    Fan B; Shen C; Wu M; Zhao J; Guo Q; Luo Y
    Medicine (Baltimore); 2018 Aug; 97(35):e12007. PubMed ID: 30170406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies.
    Aquilani R; Brugnatelli S; Maestri R; Iadarola P; Corallo S; Pagani A; Serra F; Bellini A; Buonocore D; Dossena M; Boschi F; Verri M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
    Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
    BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases.
    Oshima G; Guo N; He C; Stack ME; Poon C; Uppal A; Wightman SC; Parekh A; Skowron KB; Posner MC; Lin W; Khodarev NN; Weichselbaum RR
    Mol Ther; 2017 Jul; 25(7):1588-1595. PubMed ID: 28457664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320.
    Girod M; Geisler A; Hinze L; Elsner L; Dieringer B; Beling A; Kurreck J; Fechner H
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.
    Anandappa G; Lampis A; Cunningham D; Khan KH; Kouvelakis K; Vlachogiannis G; Hedayat S; Tunariu N; Rao S; Watkins D; Starling N; Braconi C; Darvish-Damavandi M; Lote H; Thomas J; Peckitt C; Kalaitzaki R; Khan N; Fotiadis N; Rugge M; Begum R; Rana I; Bryant A; Hahne JC; Chau I; Fassan M; Valeri N
    Clin Cancer Res; 2019 Jul; 25(13):3830-3838. PubMed ID: 30952636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer.
    Meier C; La Rocca G; Nawrot V; Fißlthaler B; Overby SJ; Hourfar K; Plotz G; Seidl C; Ziegler P; Wild P; Zeuzem S; Brieger J; Jäger E; Battmann A; Brieger A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients.
    Mjelle R; Kristensen AK; Tora S Solheim ; Westvik GS; Elvebakken H; Hofsli E
    Mol Cancer; 2024 Jun; 23(1):133. PubMed ID: 38937787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer.
    Wu S; Zhou Y; Liu P; Zhang H; Wang W; Fang Y; Shen X
    Eur J Histochem; 2021 Jun; 65(2):. PubMed ID: 34155879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
    Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
    J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
    Park HA; Edelmann D; Canzian F; Seibold P; Harrison TA; Hua X; Shi Q; Silverman A; Benner A; Macauda A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
    Int J Cancer; 2023 Nov; 153(9):1623-1634. PubMed ID: 37539667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
    Hedayat S; Cascione L; Cunningham D; Schirripa M; Lampis A; Hahne JC; Tunariu N; Hong SP; Marchetti S; Khan K; Fontana E; Angerilli V; Delrieux M; Nava Rodrigues D; Procaccio L; Rao S; Watkins D; Starling N; Chau I; Braconi C; Fotiadis N; Begum R; Guppy N; Howell L; Valenti M; Cribbes S; Kolozsvari B; Kirkin V; Lonardi S; Ghidini M; Passalacqua R; Elghadi R; Magnani L; Pinato DJ; Di Maggio F; Ghelardi F; Sottotetti E; Vetere G; Ciracì P; Vlachogiannis G; Pietrantonio F; Cremolini C; Cortellini A; Loupakis F; Fassan M; Valeri N
    Clin Cancer Res; 2024 May; 30(10):2140-2159. PubMed ID: 38376926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of resistance to oxaliplatin in cancer by a microRNA/Fem1B/Gli1 pathway.
    Su YC; Metzen LT; Vélez LM; Bournique E; Seldin M; Buisson R; Kuo WW; Huang CY; Kaiser P
    Am J Cancer Res; 2023; 13(12):6011-6025. PubMed ID: 38187042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
    Park HA; Edelmann D; Canzian F; Harrison TA; Hua X; Shi Q; Silverman A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
    Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2087-2091. PubMed ID: 35984985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.
    Tavakoli Pirzaman A; Ebrahimzadeh Pirshahid M; Babajani B; Rahmati A; Niknezhad S; Hosseinzadeh R; Taheri M; Ebrahimi-Zadeh F; Doostmohamadian S; Kazemi S
    Technol Cancer Res Treat; 2023; 22():15330338231206003. PubMed ID: 37849311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive characterization of sphere models established from colorectal cancer cell lines.
    Collura A; Marisa L; Trojan D; Buhard O; Lagrange A; Saget A; Bombled M; Méchighel P; Ayadi M; Muleris M; de Reynies A; Svrcek M; Fléjou JF; Florent JC; Mahuteau-Betzer F; Faussat AM; Duval A
    Cell Mol Life Sci; 2013 Feb; 70(4):729-42. PubMed ID: 23007843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of miR-18a in resected liver metastases of colorectal cancer and FOLFOX treatment.
    Franz C; Jötten L; Wührl M; Hartmann S; Klupp F; Schmidt T; Schneider M
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1899. PubMed ID: 37698257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.